PerkinElmer introduces 4 new ready-to-use KRAS assay kits

By staff writers

July 29, 2021 -- PerkinElmer has released four new ready-to-use AlphaLisa KRAS kits aimed at helping cancer researchers identify potential new therapeutic candidates for a wide range of prevalent cancers.

Designed to help researchers better understand KRAS protein structures and mutations, the kits all come with recombinant proteins, detection reagents, and assay buffers, according to the company.

KRAS is a prime drug target, as the KRAS mutation is found in approximately 25% of cancers, making it one of the most common gene mutations linked to cancer; the mutation can be found in different cancers from lung to colorectal to pancreatic cancers.

The validated kits can identify KRAS inhibitors in a no-wash format without any need for optimization, PerkinElmer said.

PerkinElmer posts growth in Q2
PerkinElmer posted revenue and operating income increases in its second quarter 2021.
PerkinElmer to buy Immunodiagnostic Systems
PerkinElmer announced it will acquire U.K. firm Immunodiagnostic Systems Holdings for approximately $155 million. PerkinElmer said the deal will...
PerkinElmer unveils COVID-19 rapid antigen test
PerkinElmer has launched a lateral-flow immunoassay COVID-19 antigen test, a rapid antigen test suitable for mass COVID-19 screening or for diagnosis...
PerkinElmer receives CE Mark for SARS-CoV-2 assay
PerkinElmer has received a CE Mark for its SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR) assay. Now, saliva can be designated...
PerkinElmer newborn screening test gets CE Mark
PerkinElmer has received the CE Mark for its reverse transcription polymerase chain reaction newborn screening assay.

Copyright © 2021

Last Updated np 9/1/2021 12:16:47 PM